Senate panel advances $35 private-insulin cap by 17-5 vote, but fate stays unclear
A bipartisan committee sends the $35 cap forward, yet uncertainty ahead means providers, insurers, and drug makers should brace.
By Nora Al-Subaie·· 3 min
Loading the Newsroom
Curating from trusted global sources…